Risk-adapted chemotherapy in childhood medulloblastoma

Expert Review of Anticancer Therapy

Volumn 11, Issue 5, 2011, Pages 771-780

  Varan, Ali ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

chemotherapy; children; high risk; infants; medulloblastoma; prognosis; standard risk; treatment

Indexed keywords

BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; ETOPOSIDE; HYDROXYUREA; IFOSFAMIDE; LOMUSTINE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; PROCARBAZINE; THIOTEPA; TOPOTECAN; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHILD CARE; CHILDHOOD CANCER; CHILDHOOD DISEASE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; GENOTOXICITY; HUMAN; INFANT DISEASE; INFECTION; MAINTENANCE THERAPY; MEDULLOBLASTOMA; MENTAL DEFICIENCY; METASTASIS; MULTIPLE CYCLE TREATMENT; PROGNOSIS; RADIATION DOSE; REVIEW; RISK FACTOR; SALVAGE THERAPY; SIDE EFFECT; SURVIVAL RATE; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; ANTINEOPLASTIC AGENTS; CEREBELLAR NEOPLASMS; CHILD; COMBINED MODALITY THERAPY; HUMANS; INFANT; MEDULLOBLASTOMA; PROGNOSIS; RISK FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 79955817718     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.222     Document Type: Review

References (59)

1. Blaney SM, Kun LE, Hunter J et al Tumors of the central nervous system. In: Principles and Practice of Pediatric Oncology (5th Edition). Pizzo PA, Poplack DG (Eds). Lippincott, Williams and Wilkins, PA, USA, 786-864 (2006).
2. Akyuz C, Varan A, Kupeli S et al Medulloblastoma in children: a 32-year experience from a single institution. J. Neuro-Oncol. 90, 99-103 (2008).
3. Matsutani M. Chemoradiotherapy for brain tumors: current status and perspectives. J. J. Clin. Oncol. 9, 471-474 (2004).
4. Crawford JR, MacDonald T, Packer RJ. Medulloblastoma in childhood: new biological advances. Lancet Neurol. 6, 1073-1085 (2007).
5. Kombogiorgas D, Sgouros S, Walsh AR et al. Outcome of children with posterior fossa medulloblastoma: a single institution experience over the decade 1994-2003. ChildsNerv. Syst. 23, 399-405 (2007).
6. Kortmann RD, Kiihl J, Timmermann B et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int. J. Radiation Oncology Biol. Phys. 46, 269-279 (2000).
7. Packer RJ, Goldwein J, Nicholson HS et al. Treatment of children with medulloblastoma with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group Study. J. Clin. Oncol. 17,2127-2136 (1999).
8. Packer RJ, Sutton LN, Elterman R et al Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU and vincristine chemotherapy. J. Neurosurg 81,690-698(1994).
9. Paulino AC, Melian E. Medulloblastoma and supratentorial primitive neuroectodermal tumors: an institutional experience. Cancer 86, 142-148 (1999).
10. Zeltzer PM, Boyett JM, Finlay JL et al Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized Phase III study. J. Clin. Oncol. 17, 832-845 (1999).
11. Packer RJ, Rood B, MacDonald TJ. Medulloblastoma: present concepts of stratification into risk groups. Pediatr. Neurosurg 39, 60-67 (2003).
12. Caputy AJ, McCullough DC, Manz HJ, Patterson K, Hammock MK. A review of the factors influencing the prognosis of medulloblastoma. J. Neurosurg. 66, 80-87 (1987).
13. Jenkin D, Shabanah MA, Shail EA et al Prognostic factors for medulloblastoma. Int. J. Radiat. Oncol. Biol. Phys. 47, 573-584 (2000).
14. Polkinghorn WR, Tarbell NJ. Medulloblastoma: tumotigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat. Clin. Prac. Oncol. 4, 295-304 (2007).
15. Brown RC, Gunderson L, Plenk HP. Medulloblastoma: a review of the LDS hospital experience. Cancer 40, 56-60 (1977).
16. Ater JL, van Eys J, Woo SY, Moore B 3rd, Copeland DR, Bruner J. MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children. J. Neuro-Oncol. 32, 243-252 (1997).
17. Castello MA, Clerico A, Deb G, Dominici C, Fidani P, Donfrancesco A. High-dose carbopladn in combination with etoposide (JET regimen) for childhood brain tumors. Am. J. Pediatr. Hematol. Oncol. 12, 297-300 (1990).
18. Evans AE, Jenkin RD, Sposto R et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J. Neurosurg 72, 572-582 (1990).
19. Tait DM, Thornton-Jones H, Bloom HJG, Lemerle J, Morris-Jones P. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur. J. Cancer 26, 464-469 (1990).
20. Gaynon PS, Ettinger LJ, Baum ES, Siegel SE, Krailo MD, Hammond GD. Carbopladn in childhood brain tumors: a children's cancer study group Phase II trial. Cancer 66, 2465-2469 (1990).
21. Kovnar EH, Kellie SJ, Horowitz ME et al Preirradiadon cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a Phase II study. J. Clin. Oncol. 8, 330-336 (1990).
22. Pendergrass TW, Milstein JM, Geyer JR et al. Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy. J. Clin. Oncol. 5, 1221-1231 (1987).
23. Geyer JR, Pendergrass TW, Milstein JM, Bleyer WA. Eight drugs in one day chemotherapy in children with brain tumors: a critical toxicity appraisal. J. Clin. Oncol. 6, 996-1000 (1988).
24. Packer RJ, Gajjar A, Vezina G et al Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J. Clin. Oncol. 24, 4202-4208 (2006).
25. Fossati P, Ricardi U, Orecchia R. Pediatric medulloblastoma: toxicity of current treatment and potential role of protontherapy Cancer Treatment Rev. 35, 79-96 (2009).
26. Tucker MA, D'Angio GJ, Boice JD et al Bone sarcomas linked to radiotherapy and chemotherapy in children. N. Engl. J. Med. 317, 588-593 (1987).
27. Bailey CC, Gnekow A, Wellek S et al Prospective randomized trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Pediatric Oncology (SIOP) and the German Society of Pediatric Oncology (GPO): SIOP II. Med. Pediatr. Oncol. 25, 166-178 (1995).
28. Oyharcabal-Bourden V, Kalifa C, Gentet JC et al. Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study. J. Clin. Oncol. 23, 4726-4734 (2005).
29. Taylor RE, Bailey CC, Robinson K et al Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 study. J. Clin. Oncol. 21, 1581-1591 (2003).
30. Verlooy J, Mosseri V, Bracard S et al Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study. Eur. J. Cancer 42, 3004-3014 (2006).
31. Taylor RE, Bailey CC, Robinson KJ et al Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy Eur. J. Cancer 41, 727-734 (2005).
32. Prados MD, Edwards MSB, Chang SM et al. Hyper fractionated craniospinal radiation therapy for primitive neuroectodermal tumors: results of a Phase II study. Int. J. Radiat. Oncol. Biol Phys. 43, 279-285 (1999).
33. Tabori U, Sung L, Hukin J et al Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management: a Canadian Pediatric Brain Tumor Consortium Study. Cancer 103, 1874-1880 (2005).
34. Kalifa C, Grill J. The therapy of infantile malignant brain tumors: current status?. J. Neuro-Oncol 75, 279-285 (2005).
35. Duffner PK, Horowitz ME, Krischer JP et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N. Engl. J. Med. 328, 1725-1731 (1993).
36. Jakacki RI, Feldman H, Jamison C, Boaz JC, Luerssen TG, Timmerman R. A pilot study of preirradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma. Int. J. Radiat. Oncol. Biol. Phys. 60, 531-536 (2004).
37. Grill J, Sainte-Rose C, Jouvet A et al Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol. 6, 573-580 (2005).
38. White L, Kellie S, Gray E et al. Postoperative chemotherapy in children less than 4 years of age with malignant brain tumors: promising initial response to a VETOPEC- based regimen: a study of the Australian and New Zealand Children's Cancer Study Group (ANZCCSG).J Pediatr. Hemat Oncol. 20, 125-130 (1998).
39. Geyer JR, Sposto R, Jennings M et al Muldagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the children's cancer group.J Clin. Oncol. 23,7621-7631 (2005).
40. Gajjar A, Mulhern RK, Heideman RL et al Medulloblastoma in very young children: Outcome of definitive craniospinal irradiation following incomplete response to chemotherapy. J Clin. Oncol. 12, 1212-1216 (1994).
41. Rutkowski S, Bode U, Deinlein F et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N. Engl. J. Med. 352, 978-986 (2005).
42. Thorarinsdottir HK, Rood B, Kamani N et al. Outcome for children Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue. Pediatr. Blood Cancer 48, 278-284 (2007).
43. Chi SN, Gardner SL, Levy AS et al Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma.J Clin. Oncol. 22, 4881-4887 (2004).
44. Dhall G, Grodman H, Ji L et al. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the 'Head Start' I and II protocols. Pediatr. Blood Cancer 50, 1169-1175 (2008).
45. Varan A, Akalan N, Soylemezoglu F et al Central nervous system tumors in patients under 3 years of age: treatment results of a single institute. Pediatr. Neurosurg 42, 89-94 (2006).
46. Rivera-Luna R, Lopez E, Rivera-Marquez H et al. Survival of children under 3 years old with medulloblastoma: a study from the Mexican Cooperative Group for Childhood Malignancies (AMOHP). Child Nerv. Syst. 18, 38-42 (2002).
47. Garre ML, Cama A, Bagnasco F et al Medulloblastoma variants: age-dependent occurrence and relation to Gorlin syndrome-a new clinical perspective. Clin. Cancer Res. 15,2463-2471 (2009).
48. Ridola V, Grill J, Doz F et al. High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy. Cancer 110, 156-163 (2007).
49. Valteau-Couanet D, Fillipini B, Benhamou E et al. High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of effcacy. Bone Marrow Transplant 36, 939-945 (2005).
50. Perez-Martinez A, Lassaletta A, Gonzalez-Vicent M, Sevilla J, Díaz MA, Madero L. High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. J. Neuro-Oncol. 71, 33-38 (2005).
51. Gajjar A, Chintagumpala M, Ashley D et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial . Lancet Oncol. 7, 813-820 (2006).
52. Stewart CF, Iacono LC, Chintagumpala M et al. Results of a Phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J. Clin. Oncol. 22, 3357-3365 (2004).
53. Sung KW, Yoo KH, Cho EJ et al. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr. Blood Cancer 48, 408-415 (2007).
54. Dunkel IJ, Gardner SL, Garvin JH, Goldman S, Shi W, Finlay JL. High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. Neuro-Oncol. 12, 297-303 (2010).
55. Baruchel S, Diezi M, Hargrave D et al. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent pediatric brain tumors. Eur. J. Cancer 42, 2335-2342 (2006).
56. Fouladi M, Blaney SM, Poussaint TY et al. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. Cancer 107, 2291-2297 (2006).
57. Kieran M W, Packer RJ, Onar A et al. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modifed continuous reassessment method: a pediatric brain consortium study. J. Clin. Oncol. 25, 3137-3143 (2007).
58. Spiller S, Ravanpay AC, Hahn AW, Olson JM. Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. J. Neurooncol. 79, 259-270 (2006).
59. Warren K, Jakacki R, Widemann B et al. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group. Cancer Chemother. Pharmacol. 58, 343-347 (2006).